Skip to main content

Table 4 Sputum inflammatory profile in stable state and during an exacerbation grouped according to AZM treatment or placebo treatment

From: The effect of azithromycin on sputum inflammatory markers in bronchiectasis

  

AZM

  

Placebo

 
 

Baseline

(n = 25)

Exacerbation

(n = 9)

p-value

Baseline

(n = 29)

Exacerbation

(n = 20)

p-value

MPO (ug)

81.4 (203.1)

706.9 (1718.2)

0.068

53.3 (270.2)

222.3 (2260.1)

0.015

ECP (ug)

4.0 (9.0)

27.1 (151.2)

0.068

3.6 (9)

9.3 (67.8)

0.015

IP-10 (pg)

43 (167.6)

362.6 (1299)

0.144

76.3 (149.2)

108.4 (1270.7)

0.125

MIP-1β (ng)

4.3 (6.3)

54.8 (132.5)

0.144

7.1 (14.4)

19,688.2 (83,389.0)

0.020

VEGF (pg)

1443.3 (3936.9)

14,802.6 (29,729.1)

0.144

1700.1 (3985.2)

3990.8 (41,378.1)

0.078

TNF-α (pg)

175.7 (1025)

3629.5 (22,676.3)

0.068

129.9 (1841)

2287.0 (7732.4)

0.020

IL-1RA (pg)

617.2 (2112.2)

2760.9 (3649.9)

0.465

606.7 (1578)

1867.5 (17,356.4)

0.020

IL-21 (pg)

1.8 (47)

306.2 (680.1)

0.109

8.4 (90)

59.7 (1392.0)

0.046

IL-8 (ng)

25 (101.4)

148 (407.5)

0.068

22.1 (70.3)

80.9 (239.4)

0.053

IL-1β (ng)

6 (14.7)

72.8 (140)

0.068

7.5 (41.8)

39 (392.2)

0.012

IL-6 (pg)

0 (922.3)

290.5 (1705.2)

0.109

63.9 (504.8)

29.2 (809)

0.937

GCSF (pg)

0 (129.9)

0 (992.9)

0.180

0 (26.1)

0 (35.6)

0.173

GRO-α (pg)

9 (418.4)

155.8 (1753.3)

1.000

17 (170)

0 (289.7)

0.594

IL-1α (pg)

286.8 (717.4)

1829.7 (3282.2)

0.068

285.3 (1071.9)

1069.1 (3207.4)

0.015

MIP-3α (pg)

0 (236)

101 (1754.3)

0.180

0 (64)

67.6 (215.4)

0.463

MMP-9 (ng)

194.9 (328.5)

851.8 (2389.9)

0.144

177.1 (375.1)

337 (2311.3)

0.061

  1. Data are presented as median with inter quartile range (IQR)
  2. Abbreviations: AZM Azithromycin